Literature DB >> 19107353

Packaging and functional identification of recombinant adeno-associated virus encoding cdc2-siRNA.

Jiajun Wei1, Min Zhang, Bitao Bu, Suming Zhang, Jinzhi Xu.   

Abstract

Cyclin dependent kinases (cdks) play an important role in the pathogenesis of multiple neurodegenerative diseases. To explore the possibility of cdks-related gene therapy for neurodegenerative diseases, we packed recombinant adeno-associated virus (rAAV) encoding cdc2-siRNA. The expressing plasmid pAAV-MCS-EGFP-U6-cdc2-siRNA was constructed by using molecular biological techniques. The rAAV encoding cdc2-siRNA (rAAV-EGFP-U6-cdc2-siRNA) was packed by calcium phosphate mediated co-transfection of the plasmid pAAV-MCS-EGFP-U6-cdc2-siRNA, p-RC and p-Helper into AAV-293 cells. DNA sequencing proved the successful construction of U6-cdc2-siRNA in pAAV-MCS-EGFP. Seventy-two h after packaging, the expression of EGFP could be detected in AAV-293 cells. Western blotting revealed that cdc2 gene expression in AAV-293 cells was down-regulated markedly after transfection with rAAV-EGFP-U6-cdc2-siRNA, which evidenced the satisfactory silencing effect of this virus. It was concluded that the packaging of rAAV encoding cdc2-siRNA was successful. rAAV encoding cdc2-siRNA could silence cdc2 gene effectively, which might offer a novel means for the treatment of neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19107353     DOI: 10.1007/s11596-008-0602-y

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  17 in total

1.  Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain.

Authors:  I Vincent; G Jicha; M Rosado; D W Dickson
Journal:  J Neurosci       Date:  1997-05-15       Impact factor: 6.167

Review 2.  RNA interference.

Authors:  Gregory J Hannon
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

Review 3.  Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors.

Authors:  T R Flotte
Journal:  Gene Ther       Date:  2004-05       Impact factor: 5.250

4.  Neuronal cell cycle re-entry mediates Alzheimer disease-type changes.

Authors:  Andrew McShea; Hyoung-gon Lee; Robert B Petersen; Gemma Casadesus; Inez Vincent; Nancy J Linford; Jens-Oliver Funk; Robert A Shapiro; Mark A Smith
Journal:  Biochim Biophys Acta       Date:  2006-10-03

5.  siRNA-mediated gene silencing in vitro and in vivo.

Authors:  Haibin Xia; Qinwen Mao; Henry L Paulson; Beverly L Davidson
Journal:  Nat Biotechnol       Date:  2002-09-16       Impact factor: 54.908

6.  Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice.

Authors:  Min Zhang; Jin Li; Paramita Chakrabarty; Bitao Bu; Inez Vincent
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

7.  Recombinant adeno-associated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries.

Authors:  T Wang; H Li; C Zhao; C Chen; J Li; J Chao; L Chao; X Xiao; D W Wang
Journal:  Gene Ther       Date:  2004-09       Impact factor: 5.250

8.  Cdk5 is a key factor in tau aggregation and tangle formation in vivo.

Authors:  Wendy Noble; Vicki Olm; Kazuyuki Takata; Evelyn Casey; O Mary; Jordana Meyerson; Kate Gaynor; John LaFrancois; Lili Wang; Takayuki Kondo; Peter Davies; Mark Burns; Ralph Nixon; Dennis Dickson; Yasuji Matsuoka; Michael Ahlijanian; Lit-Fui Lau; Karen Duff
Journal:  Neuron       Date:  2003-05-22       Impact factor: 17.173

9.  Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1.

Authors:  Minh Dang Nguyen; Mathieu Boudreau; Jasna Kriz; Sebastien Couillard-Després; David R Kaplan; Jean-Pierre Julien
Journal:  J Neurosci       Date:  2003-03-15       Impact factor: 6.167

Review 10.  Gene therapy: recombinant adeno-associated virus vectors.

Authors:  J R Smith-Arica; J S Bartlett
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 3.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.